{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:38:09Z","timestamp":1783953489608,"version":"3.55.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1097\/ftd.0000000000000271","type":"journal-article","created":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T14:10:24Z","timestamp":1451484624000},"page":"343-349","source":"Crossref","is-referenced-by-count":26,"title":["Effects of UGT2B7 Genetic Polymorphisms on Serum Concentrations of Valproic Acid in Chinese Children With Epilepsy Comedicated With Lamotrigine"],"prefix":"10.1097","volume":"38","author":[{"given":"Qiuning","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homgmei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10","volume":"37","author":"Argikar","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"R2-10-20210129","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/FPC.0b013e3283037fe4","article-title":"Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene","volume":"18","author":"Innocenti","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R3-10-20210129","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/FTD.0000000000000012","article-title":"Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients","volume":"36","author":"Inoue","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R4-10-20210129","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/pgs.11.64","article-title":"Association of genetic variants in six candidate genes with valproic acid therapy optimization","volume":"12","author":"Hung","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R5-10-20210129","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","article-title":"Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes","volume":"132","author":"Daly","year":"2007","journal-title":"Gastroenterology"},{"key":"R6-10-20210129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.tpj.6500139","article-title":"Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients","volume":"3","author":"Holthe","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"R7-10-20210129","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/sj.clpt.6100073","article-title":"The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers","volume":"81","author":"Levesque","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R8-10-20210129","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.tpj.6500327","article-title":"Clinical response to morphine in cancer patients and genetic variation in candidate genes","volume":"5","author":"Ross","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"R9-10-20210129","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00228-012-1277-7","article-title":"Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"68","author":"Chu","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R10-10-20210129","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","article-title":"Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy","volume":"27","author":"Guo","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"R11-10-20210129","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.clpt.6100324","article-title":"Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects","volume":"83","author":"Chung","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R12-10-20210129","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/0091270009338482","article-title":"Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB\/HIV-coinfected ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation","volume":"49","author":"Kwara","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R13-10-20210129","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1248\/bpb.30.2146","article-title":"Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity","volume":"30","author":"Takekuma","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"R14-10-20210129","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R15-10-20210129","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1472-8206.2000.tb00411.x","article-title":"Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies","volume":"14","author":"Benedetti","year":"2000","journal-title":"Fundam Clin Pharmacol"},{"key":"R16-10-20210129","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.dmpk.2014.12.007","article-title":"Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy","volume":"30","author":"Wang","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"R17-10-20210129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clpt.2003.10.006","article-title":"A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity","volume":"75","author":"Duguay","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R18-10-20210129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2217\/pgs.11.141","article-title":"Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization","volume":"13","author":"Hung","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R19-10-20210129","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0090-9556(24)02990-8","article-title":"Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population","volume":"32","author":"Saeki","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"R20-10-20210129","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0009-9236(03)00053-5","article-title":"A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine","volume":"73","author":"Sawyer","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R21-10-20210129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.50.2.259","article-title":"Developmental aspects of human hepatic drug glucuronidation in young children and adults","volume":"50","author":"Strassburg","year":"2002","journal-title":"Gut"},{"key":"R22-10-20210129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.eplepsyres.2006.04.002","article-title":"The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: a case-matched evaluation based on therapeutic drug monitoring data","volume":"70","author":"Fattore","year":"2006","journal-title":"Epilepsy Res"},{"key":"R23-10-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0009-9236(96)90130-7","article-title":"Bidirectional interaction of valproate and lamotrigine in healthy subjects","volume":"60","author":"Anderson","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"R24-10-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/157488611794480061","article-title":"The effect of lamotrigine on valproic acid concentrations","volume":"6","author":"Martin","year":"2011","journal-title":"Curr Drug Saf"},{"key":"R25-10-20210129","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1528-1157.1996.tb00650.x","article-title":"Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy","volume":"37","author":"Eriksson","year":"1996","journal-title":"Epilepsia"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T23:47:48Z","timestamp":1748735268000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201606000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000271","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}